We aimed to estimate the proportion of patients with diabetes who achieved target glycemic control, to estimate diabetes-related costs attributable to poor control, and to identify factors associated with them in the United Arab Emirates. Methods: This retrospective cohort study used administrative claims data handled by Abu Dhabi Health Authority (January 2010 to June 2012) to determine glycemic control and diabetes-related treatment costs. A total of 4,058 patients were matched using propensity scores to eliminate selection bias between patients with glycosylated hemoglobin (HbA1c) <7% and HbA1c ≥7%. Diabetes-related costs attributable to poor control were estimated using a recycled prediction method. Factors associated with glycemic control were investigated using logistic regression and factors associated with these costs were identified using a generalized linear model. Results: During the 1-year follow-up period, 46.6% of the patients achieved HbA1c <7%. Older age, female sex, better insurance coverage, non-use of insulin in the index diagnosis month, and non-use of antidiabetic medications during the follow-up period were significantly associated with improved glycemic control. The mean diabetes-related annual costs were $2,282 and $2,667 for patients with and without glycemic control, respectively, and the cost attributable to poor glycemic control was $172 (95% confidence interval [CI], $164-180). The diabetes-related costs were lower with mean HbA1c levels <7% (cost ratio, 0.94; 95% CI, 0.88-0.99). The costs were significantly higher in patients aged ≥65 years than those aged ≤44 years (cost ratio, 1.45; 95% CI, 1.25-1.70). Conclusion: More than 50% of patients with diabetes had poorly controlled HbA1c. Poor glycemic control may increase diabetes-related costs.
INTRODUCTION
Diabetes mellitus is a major chronic disease affecting an estimated 382 million people globally in 2013 1 tality by 21% and microvascular complications by 37%. 10 Because of the importance of glycemic control in patients with diabetes, the American Diabetes Association and UAE diabetes management guidelines recommend a specific HbA1c target of <7% for adults with diabetes. 3, 11 However, the proportion of patients with good glycemic control remains low, despite the importance of glycemic control. In the United States, the proportion of adults with HbA1c <7% was only 53% of patients with diabetes in 2007-2010, despite an increase over time 12 , and only 33.3% of adults with diagnosed diabetes in the UAE achieve the glycemic goal. 13 Diabetes also presents a huge economic burden, with a total estimated cost of $245 billion in 2012 in the U.S. and treatment costs that are estimated at 2.3 times that of people without the disease. 14 In Al Ain, UAE, the total annual direct medical costs of diabetes among patients without complications were estimated to be 3.2 times higher than the per capita health care expenditure, and the costs increased even further with the presence of complications. 15 Furthermore, elevated HbA1c levels are associated with substantial medical costs, which increase even further with increases in HbA1c levels. 16 There is considerable evidence that improved glycemic control results in medical cost savings 17 ; a sustained reduction in HbA1c in adults with diabetes is associated with significant cost savings within the first 1-2 years of improvement. 18 Although a number of studies have examined the relationship between patient characteristics, glycemic control, and the diabetesrelated treatment costs [7] [8] [9] [19] [20] [21] , little is known about factors influencing glucose control and diabetes-related costs in patients with diabetes in the UAE. Therefore, the objectives of this study were to estimate the proportion of patients with diabetes who achieve the glycemic target, to identify factors associated with poor glycemic control, to estimate diabetes-related costs attributable to glycemic control, and to identify the characteristics associated with diabetesrelated costs in patients newly diagnosed diabetes in the UAE.
METHODS

Data source and study population
This study is a retrospective cohort analysis using the knowledge engine of health administrative claims database handled by Abu Dhabi Health Authority. The Abu Dhabi Health Authority is the regulatory body of the Emirate's healthcare system established to monitor the health status of its residents and ensure the quality of healthcare for its community. Knowledge engine of health administrative claims database is a platform built to collect health-related information and encounter claims data of the residents that can be analyzed for health status monitoring, regulation, and policy-making purposes. The data set consists of administrative information, diagnoses, activity, and observation elements. Administrative information describes the patients and claims, including financial data and encounters. Activity data include consultations and diagnostic and treatment activities, whereas observation data include specific observations as a result of medical activities (e.g., a lab test).
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Data comprised all administrative health claims from January 2010 to June 2012. Eligible patients with diabetes were defined as patients (1) who met specified inclusion criteria for new diabetes diagnosis including type 1, type 2, and unspecified type during the enrollment period from July 2010 to June 2011; (2) who were not diagnosed with diabetes during the 6 months prior to the index month; (3) who can be followed up for at least 1 year from the index month; and (4) who had at least two HbA1c values, including the baseline HbA1c level during the follow-up period. The index month was defined as the first month of diagnosis for diabetes during the enrollment period, and the identified patients with diabetes were followed for 1 year from the index month. 
Study variables
The primary study outcome variable was glycemic control and the secondary outcome variable was annual diabetes-related costs.
Glycemic control was defined as achievement of a follow-up HbA1c <7%. 11 Baseline HbA1c level was measured during the index month, and the follow-up HbA1c level was defined as the average of the HbA1c values measured during the follow-up period.
This study examined the impact of glycemic control on diabetesrelated costs. Diabetes-related costs were calculated by adding medical and prescription costs for the treatment of diabetes and diabetes-related comorbidities, such as nephropathy, neuropathy, retinopathy/macular edema, cardiovascular disease, cerebrovascular disease, and skin disease, during the follow-up period. Medical costs included costs related to hospitalization, outpatient services, and emergency department visits. The costs include net charges billed by the healthcare provider to the payer and any fee that the payer was expecting the healthcare provider to collect from the patient.
Statistical analysis
The patients were stratified based on glycemic control (HbA1c <7% vs. HbA1c ≥7%) using the mean HbA1c level measured during the 1-year follow-up period. The demographic and clinical characteristics included age, sex, nationality, health insurance plan, insulin use in the index diagnosis month, use of antidiabetic medications, and comorbidities diagnosed during the study period (i.e., the pre-index period during the 6 months prior to the index month and the 1-year follow-up period). Insulin use in the index month was an indicator variable to identify whether the patient was prescribed insulin in the index month. The use of antidiabetic medications was an indicator variable to identify whether the patient was prescribed any diabetic medication during the follow-up period.
Finally, comorbidities during the study period included hypertension, hyperlipidemia, hypoglycemia, nephropathy, neuropathy, cardiovascular disease, cerebrovascular disease, obesity, rheumatoid arthritis (RA)/osteoarthritis (OA), and asthma/chronic obstructive pulmonary disease (COPD).
The demographic and clinical characteristics of the two patient groups (HbA1c <7% vs. HbA1c ≥7%) were compared using chisquare test. To adjust for these differences, the patients with glycemic control (HbA1c <7%) were matched to those without glycemic control (HbA1c ≥7%) using a propensity score. The propensity score, which is the conditional probability of assigning a patient to the group with glycemic control, was calculated to balance the patient characteristics of the two groups and therefore reduce the selection bias. 23 A logistic regression was used to estimate the propensity score for each patient after adjusting the confounding variables such as nationality, health insurance plan, the use of insulin and oral antidiabetic medications in the index month, and comorbidities during the pre-index period.
Matching between the two groups was implemented by a 1:1 ratio using a greedy matching method, which pairs each case patient with a unique comparison patient based on the closest propensity scores without replacement. 24 The patients in each group were stratified by age (four blocks) and sex (two blocks) in order to enhance the precision of the matching. Within each stratified block, patients with glycemic control were initiated to match on a 1:1 ratio with those without glycemic control on the basis of identical six-digit propensity scores, and continued until patients were matched with at least identical two-digit scores. If a patient with glycemic control had more than one match in the group without glycemic control, one of the patients without glycemic control was randomly selected. The mean c-statistic, which was calculated to ensure the ability of the propensity scores to effectively differentiate between the two groups, was 0.73 (range, 0.68-0.81).
To investigate the economic impact of glycemic control, diabetes-related costs were compared between the two groups. For the matched patients, the average annual diabetes-related cost per patient was calculated, and 95% confidence intervals (CIs) were obtained using the bootstrap method because they did not follow the normal distribution. 25 A paired t-test was used to detect statistically significant differences in diabetes-related costs between the two matched patients. Additionally, to examine the influence of age on diabetes-related costs between the two groups, the costs were compared by age groups (i.e., ≤ 44, 45-54, 55-64, or ≥ 65 years). Diabetes-related costs attributable to glycemic control were defined as the difference in predicted diabetes-related costs between patients with glycemic control versus those without glycemic control, which were estimated using a recycled prediction method.
First, the coefficients of the covariates (i.e., HbA1c control, age, sex, nationality, region, health insurance plan, insulin use in the index month, use of antidiabetic medications, and comorbidities during the study period) were calculated using GLM for diabetes-related costs in all matched patients. Once the coefficients were calculated, the diabetes-related costs for patients with glycemic control were predicted under the assumption that all matched patients had gly- cemic control (i.e., dummy variable for HbA1c control was 0).
Similarly, the costs for patients without glycemic control were predicted under the assumption that all matched patients did not have glycemic control (i.e., dummy variable for HbA1c control was 1).
The differences between the two predicted costs were identified as the diabetes-related costs attributable to glycemic control in patients with diabetes. [26] [27] [28] All costs were converted to 2015 UAE dirhams (AED) using the consumer price index and to US dollars using the exchange rate (USD 1 = AED 3.67). Data were analyzed using SAS ver. 9.2 (SAS Institute, Cary, NC, USA) and STATA ver. 10.1 (STATA Corp., College Station, TX, USA). HbA1c. However, after matching these two groups using the propensity scores, differences in all characteristics of two group patients could not be found.
RESULTS
Annual total treatment costs in patients with controlled glycemic level were $3,285, while total costs were $3,315 in patients with uncontrolled glycemic level ( Table 2 ). Of these total costs, the diabetes-related costs were $2,282 and $2,667 per year for patients with HbA1c <7% and HbA1c ≥7%, respectively. In both groups, two-thirds of the diabetes-related costs were medical costs, of which outpatient visits were the biggest component. In the analysis of the diabetes-related costs stratified by patients' age after matching ( Fig. 1) , the difference in diabetes-related costs between patients with and without glycemic control was smallest in the 45-54 year age group ($2,088 vs. $2,217), and the difference increased with age. In general, Table 3 presents that the diabetes-related costs attributable to poor glycemic control were estimated at $172 (95% CI, $164-180), which were defined as the difference in the costs between patients with HbA1c ≥7% and patients with HbA1c <7%
after adjustment for differences in covariates between matched patient groups using the recycled prediction method. Table 4 presents that factors influencing glycemic control and di- Table 4 also present cost ratios associated with diabetes treatment after adjusting for the study variables. Diabetes-related treatment costs in patients with controlled glycemic level (HbA1c < 7%) were 6% lower than those of patients with uncontrolled gly- *Costs attributable to the uncontrolled HbA1c were the differences in the predicted costs between patients with controlled glycemic level (< 7%) and patients with uncontrolled glycemic level; † Predicted costs were calculated using a generalized linear model with a log link function and gamma distribution. CI, confidence interval; HbA1c, glycosylated hemoglobin. *ORs of controlling of HbA1c level were estimated using logistic regression after adjusting for the study variables; † Diabetes-related costs were estimated using a generalized linear model with a log link function and gamma distribution. HbA1c, glycosylated hemoglobin; OR, odds ratio; CI, confidence interval; RA, rheumatoid arthritis; OA, osteoarthritis; COPD, chronic obstructive pulmonary disease. 
DISCUSSION
In our analysis, 46.6% of patients with diabetes residing in Abu Dhabi, UAE achieved the HbA1c goal of < 7% during the 1-year follow-up period, which is higher than previous observations in other populations: 33.3% in the Al Ain Emirate of the UAE 13 ,
34.9% in Jordan
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, 31% in the United Kingdom (HbA1c ≤ 7.5%) 9 , and 29% of patients with diabetes receiving medical treatment in a managed care setting in the United States. 30 In the present study, the higher rate of glycemic control in Abu Dhabi is primarily explained by the selection of patients with diabetes in the first year of their disease.
Several patient characteristics influenced glycemic control. Similar to previous studies that showed that younger age was associated with worse glycemic control in diabetes 7, 8, 19, 31 , patients aged ≥ 65 years were 30% more likely to have good glycemic control than patients <44 years old. This might be due in part to higher HbA1c levels in early onset diabetes patients compared with late onset patients. 32 Second, older adult patients with T2DM might have improved adherence to oral antidiabetic medications. 33 A 10% increase in adherence to oral antidiabetic medications was associated with a 0.1% decrease in HbA1c, when controlled for baseline HbA1c and therapy regimen. 33 In our analysis, female patients with diabetes had better glycemic control, which was consistent with a study conducted in the United States 8 but not with studies conducted in Finland and Saudi Arabia. 34, 35 Thus, sex-related cultural differences might also affect glycemic control.
Socioeconomic situation might also influence the patients' ability to regulate glycemic levels. The Enhanced and Thiqa insurance plans, which represent the best health insurance coverage in UAE,
were significantly associated with better glycemic control than the Basic plan. Similarly, the prevalence of poor glycemic control was highest among the uninsured in the United States 19 , including higher
HbA1c levels in the uninsured in a low-income, multiethnic population with T2DM in the San Diego County. 7 Also, the type of insurance coverage was a risk factor for sustained poor glycemic control in patients with type 1 diabetes in Hawaii. taking no medication or oral medications only. 7, 9, 29 Compared with the use of only oral antidiabetic agents, the odds of poor glycemic control were four times higher with insulin alone and 7.5 times higher with combined oral antidiabetic agents and insulin. 29 Furthermore, sustained poor glycemic control was observed in patients with diabetes taking more medication of any kind. 31 Insulin use could represent disease severity to some extent. Diabetes duration could also be used to indicate disease severity, and there is considerable evidence indicating that longer diabetes durations are related with poor glycemic control. 7, 29, 31, 36 However, owing to the short follow-up period, the relationships between the onset of diabetes, diabetes duration, and glycemic control could not be examined in our and non-diabetes-related comorbidities.
A mean HbA1c <7% during the follow-up period was associated with 25% lower diabetes-related costs, which supports previous research reporting significant relationships between uncontrolled HbA1c and increased health care costs in patients with T2DM. 20, 21, 37 In a large managed care setting in the United States, the estimated total diabetes-related cost during the 1-year follow-up period was $1,594 per patient with T2DM and HbA1c >7%, which was 32%
higher than the costs for those achieving the glycemic target. 37 In our analysis, a patient with HbA1c <7% incurred 32% less prescription drug costs and 22% less medical costs related to diabetes than a patient with HbA1c ≥ 7%. Similarly, a patient with T2DM
and HbA1c ≤7% incurred 20% less direct medical costs attributable to diabetes and 11% less antidiabetic prescription drugs costs annually than a patient with HbA1c >9% in a US-based study. 21 The impact of glycemic control on costs may be a result of medication adherence. Previous research showed that good adherence to insulin in patients with insulin-dependent diabetes was associated with reduced hospital admissions for diabetic ketoacidosis and all hospital admissions related to acute diabetes complications in patients with insulin-dependent diabetes. 38 Diabetes-related costs were higher in elderly patients ( ≥65 years) and those of UAE nationality as well as with better health insurance coverage and the use of insulin and antidiabetic medications in the index diagnosis month. The positive association between patient's age and diabetes-related costs was previously observed in the UAE and other countries. 15, 20 The association between insurance coverage and costs in patients with diabetes was also noted in the United States
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; compared with only Medicare insurance, additional commercial health insurance was associated with higher diabetes-related medical and prescription drug costs. In the UAE, the direct medical costs of diabetes and its complications increase with diabetes duration and the use of insulin. 15 Moreover, Brandle et al. 39 estimated that a patient with T2DM treated with oral antidiabetic medications or insulin had 1.10 or 1.59 times, respectively, the direct medical costs of a patient with diet-controlled diabetes. In addition, most comorbidities in the present study increased diabetes-related costs, which was consistent with previous , self-care behaviors such as glucose monitoring 29 and lifestyle (diet, exercise, smoking, drinking) 29, 36 because the information was not available in the data set. Second, we could consider the time from the initial diagnosis of diabetes, which can influence the response to antidiabetic medication, level of glycemic control, onset of complications, and diabetes-related costs. Instead, we attempted to include only new patients with diabetes; however, the length of the pre-index period (6 months) may be too short to exclude patients with a previous diagnosis of diabetes. Third, this study may be subject to misclassification bias in the claims database. Also, the cost analysis was based on diagnostic codes of diabetes and the use of antidiabetic drugs. This may have resulted in underestimation of total costs associated with diabetes. Further studies using large datasets and longer follow-up periods are needed to determine causality and control for important confounders such as diabetes severity.
In the capital of the UAE (Abu Dhabi), 46.6% of patients with mild diabetes were able to maintain their HbA1c level below the recommended 7% over the first year of the disease. Diabetes-related costs were higher in patients with poorly controlled diabetes, which significantly increased with age. Glycemic control was associated with lower costs in patients enrolled in the Enhanced or Thiqa insurance plan. However, diabetes-related costs were higher for the patients enrolled in these plans, compared with the Basic plan, suggesting that financial situation might limit the ability to delay disease progression. Thus, it may be advantageous to improve the coverage of the Basic plan at an affordable cost for low-income patients to reduce the future expenses associated with the treatment of severe disease complications.
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